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Abstract
Background: Salivary (AMY1) and pancreatic (AMY2) amylases hydrolyze starch. Copy number of AMY1A (encoding
AMY1) was reported to be higher in populations with a high-starch diet and reduced in obese people. These results
based on quantitative PCR have been challenged recently. We aimed to re-assess the relationship between amylase
and adiposity using a systems biology approach.
Methods: We assessed the association between plasma enzymatic activity of AMY1 or AMY2, and several metabolic
traits in almost 4000 French individuals from D.E.S.I.R. longitudinal study. The effect of the number of copies of AMY1A
(encoding AMY1) or AMY2A (encoding AMY2) measured through droplet digital PCR was then analyzed on the same
parameters in the same study. A Mendelian randomization analysis was also performed. We subsequently assessed the
association between AMY1A copy number and obesity risk in two case-control studies (5000 samples in total). Finally,
we assessed the association between body mass index (BMI)-related plasma metabolites and AMY1 or AMY2 activity.
Results: We evidenced strong associations between AMY1 or AMY2 activity and lower BMI. However, we found a
modest contribution of AMY1A copy number to lower BMI. Mendelian randomization identified a causal negative effect of
BMI on AMY1 and AMY2 activities. Yet, we also found a significant negative contribution of AMY1 activity at baseline to
the change in BMI during the 9-year follow-up, and a significant contribution of AMY1A copy number to lower obesity
risk in children, suggesting a bidirectional relationship between AMY1 activity and adiposity. Metabonomics identified a
BMI-independent association between AMY1 activity and lactate, a product of complex carbohydrate fermentation.
Conclusions: These findings provide new insights into the involvement of amylase in adiposity and starch metabolism.
Keywords: AMY1A/AMY2A, Body mass index, Copy number variant, Mendelian randomization, Metabonomics, Obesity,
Salivary/Pancreatic amylase, Starch
Background
Amylase is responsible for starch hydrolysis, initiating
carbohydrate digestion in the oral cavity and later in the
gut. In humans, approximately half of the amylase
activity found in serum is produced by the salivary
glands and the remaining part by the exocrine pancreas
[1] from different genes located in the same complex
chromosome 1 locus.
A well-known multi-allelic copy number variant at
salivary amylase gene (AMY1A; diploid copy number
ranging from one to roughly 20) evolved as an adaptation
to dietary habits [2]. Populations with high starch con-
sumption carry larger number of copies than others that
have maintained an ancestral pre-agricultural way of life
[2]. Previously, we reported that AMY1A copy number
estimated by quantitative RT-PCR (qPCR) is associated
with body mass index (BMI) in North European and
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South Asian adult populations [3]. It provided a putative
genetic link between complex carbohydrate metabolism in
the gut and obesity. This association was replicated in
early-onset obese females from Finland [4] and in pre-
pubertal boys in Italy [5], and an association with insulin
resistance was reported in adult Korean men [6], where
AMY1A copy number was also estimated by qPCR. On
the other hand, using digital PCR, two studies failed to re-
produce these findings [7, 8]. Usher et al. [7] suggested
that the discrepancy with the previously reported observa-
tions likely comes from their higher-resolution approaches
for both molecular and computational analyses. Recently,
however, using digital PCR, we have found that, in Mexican
children with high-starch diet, high number of AMY1A
copies significantly protects against obesity in this popula-
tion [9]. Finally, a study that used fiber-FISH suggested a
role for copy number of pancreatic amylase genes (AMY2A
and AMY2B) in the observed functional associations [10].
This debate is important for several reasons. First,
chromosome structural variants are increasingly recognized
to highly contribute to disease development [11], and thus
the correct genotyping of multi-allelic copy number variant
is mandatory [12]. Second, it was shown that non-obese
adults with high salivary amylase activity (and putatively
high AMY1A copy number) present with improved glucose
tolerance following liquid starch ingestion [13]. Further-
more, high serum amylase activity was shown to be associ-
ated with decreased risk of metabolic syndrome and type 2
diabetes in a Japanese asymptomatic population [14].
Finally, in more than 100 different strains of mice fed a
high-fat, high-sucrose diet, the Amy1 locus was reported to
be significantly associated with weight gain variation and
with an enrichment of obesity-associated bacteria of gut
microbiota [15]. Therefore, it is crucial to robustly deter-
mine if amylase activities (and amylase gene copy number)
impact energy and glucose homeostasis.
In the present study, we employed a systems biology
approach, using genetics, protein activity and metabo-
nomics analyses, to decipher the putative interaction be-
tween amylase genes and adiposity in human population.
We first assessed the association between plasma enzymatic
activity of salivary (AMY1) or pancreatic (AMY2) amylase,
and several metabolic traits, including BMI. We then ana-
lyzed the effect of AMY1A or AMY2A copy number on the
same parameters. A Mendelian randomization analysis was
subsequently performed to assess causality effects explain-
ing the complex relationship between BMI and AMY1 or
AMY2 plasma enzymatic activity, and actually suggested a
bidirectional causal negative effect in the relationship be-
tween BMI and AMY1 plasma enzymatic activity. We sub-
sequently confirmed an association between AMY1A copy
number and reduced obesity risk in children. Finally, we
assessed the association between BMI-related plasma me-




D.E.S.I.R. is a 9-year longitudinal study in a French general
population, fully described elsewhere [16]. A total of 4834
unrelated individuals who were successfully genotyped
through iSelect Metabochip DNA microarrays (Illumina,
San Diego, CA, USA) was included in the present study.
AMY1A copy number and AMY2A copy number were
successfully genotyped in 3607 and 3657 participants, re-
spectively. At baseline, we had access to AMY1 plasma en-
zymatic activity for 3744 participants. Among them, we had
access to AMY1 plasma enzymatic activity after 9 years of
follow-up for 679 individuals, to BMI after 9 years of follow-
up for 2796 individuals, and to the levels of BMI-associated
plasma metabolites at baseline for 718 individuals. More-
over, we had access to AMY2 plasma enzymatic activity at
baseline for 3980 participants. Among them, we had access
to AMY2 plasma enzymatic activity after 9 years of follow-
up for 705 individuals, to BMI after 9 years of follow-up for
2970 individuals, and to the levels of BMI-associated plasma
metabolites at baseline for 718 individuals. Additional file 1
recapitulates all these numbers. Non-diabetic participants
did not use glucose lowering medication, and presented with
fasting plasma glucose less than 7 mmol/L and glycated
hemoglobin A1c less than 6.5% [17].
The Biological Atlas of Severe Obesity study (ABOS)
ABOS is a cohort study (ClinicalGov NCT01129297) from
the University Hospital of Lille, France, fully described
elsewhere [18]. In the present study, we measured plasma
enzymatic activity of AMY1 and AMY2 in 488 participants
who were also genotyped through Metabochip DNA micro-
arrays (Illumina).
Obesity case-control studies
Clinical characteristics of study participants are shown in
Additional file 2. The first case-control study included 2220
normal-weight adults (with a BMI < 25 kg/m2) and 1179
adults presenting with obesity (with a BMI ≥ 30 kg/m2).
These adults were from D.E.S.I.R. or were recruited either
by the CNRS UMR8199 (Lille, France), by the Department
of Nutrition of Hotel-Dieu Hospital (Paris, France), or by
the Centre d'Etude du Polymorphisme Humain (CEPH,
Saint-Louis hospital, Paris, France). The second case-control
study included 712 normal-weight children or adolescents
(with a BMI-for-age < 85th percentile) and 785 children or
adolescents presenting with obesity (with a BMI-for-age ≥
99th percentile). These children or adolescents were from
the French Haguenau regional cohort study [19] or from the
French Fleurbaix-Laventie Ville Santé study [20], or they
were recruited by the CNRS UMR8199 (Lille, France).
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Estimation of AMY1A and AMY2A copy number
Copy number of AMY1A and AMY2A was estimated
using the QX200 droplet digital PCR (ddPCR) system
(Bio-Rad Laboratories, Hercules, CA, USA), following the
manufacturer’s recommendations. Concentration of DNA
samples was measured using the Qubit ds DNA Assay HS
kit (Life Technologies, Carlsbad, CA, USA). Dilutions
were performed with 20× GE Sample Loading Reagent
(Fluidigm, South San Francisco, CA, USA). Each 40 μL re-
action included 11 μL ddPCR SuperMix for Probes no
dUTP (Bio-Rad), 24 ng DNA (for AMY1A copy number
estimation) or 32 ng DNA (for AMY2A copy number
estimation), 1.1 μL of TaqMan assay targeting AMY1A or
AMY2A (Hs07226362_cn or Hs04204136_cn, respectively;
Life Technologies), 1.1 μL of TaqMan assay targeting the
reference RNase P assay (Human RNase P #4403328; Life
Technologies), and 0.5 U HindIII (High Fidelity; New Eng-
land Biolabs, Ipswich, MA, USA). Of note, both AMY1A
and AMY2A target assays utilized FAM-labeled probes,
while RNase P assay was labeled in VIC. Enzymatic
digestion was done for 5 minutes at 20 °C. Subsequently,
the reaction was emulsified with Droplet Generator Oil
(Bio-Rad) using the QX200 Droplet Generator (Bio-Rad),
following the manufacturer’s instructions. The droplets
were then transferred to a 96-well reaction plate (Eppen-
dorf) and PCR amplification was performed using a Veriti
Thermal Cycler (Life Technologies). After amplification,
droplets were read using a QX200 Droplet Reader
(Bio-Rad). Fluorescence data were analyzed using Quanta-
Soft software (version 1.7.4, Bio-Rad). Only samples with
at least 7000 droplets were kept for further analyses.
Measurement of plasma enzymatic activities of salivary
(AMY1) and pancreatic (AMY2) amylases
Plasma enzymatic activities of total amylase and AMY2
were estimated by an enzymatic colorimetric assay with an
autoanalyzer (CoBAS Icobas 8000 modular analyzer series;
kits #AMY-P-20766623322 and #AMYL2-03183742122;
Hoffman-La Roche, Basel, Switzerland). The plasma en-
zymatic activity of AMY1 was calculated by subtracting the
activity of AMY2 from the activity of total amylase.
Normal ranges of the plasma enzymatic activities of AMY2
and total amylase were 13–53 U/L and 29–99 U/L, re-
spectively. Only individuals presenting with these normal
ranges were analyzed.
Measurement of plasma metabolites
Fasting plasma samples were processed by the Metabolon
(Durham, NC, USA) platform using gas chromatography
mass spectrometry and liquid chromatography-tandem
mass spectrometry, as previously described [21, 22]. In the
present study, we only analyzed 36 metabolites previously
shown to be associated with BMI [23], including 1,5-anhy-





xyisovalerate, andro steroid monosulfate 2, asparagine,
benzoate, butyrylcarnitine, carnitine, gamma-glutamyli
soleucine, gamma-glutamyltyrosine, glutamate, glycerol,
glycine, hexanoylcarnitine, histidine, isoleucine, isovaleryl-
carnitine, kynurenine, lactate, lathosterol, leucine, man-
nose, N-acetylglycine, palmitoyl sphingomyelin, phenyla
lanine, propionylcarnitine, tyrosine, and valine. These
metabolites presented with a missing value rate of less
than 5%. The missing values were imputed with the smal-
lest detected value. We were unable to analyze the BMI-
associated metabolite 1-eicosadienoylglycerophosphochol
ine [23], as it was undetectable in the present study cohort.
Statistical analyses
Ethnic characterization
Ethnic characterization of each participant was assessed
using the iSelect Metabochip DNA microarrays (Illumina),
as previously described [24].
Association analyses between AMY1/AMY2 plasma
enzymatic activity or AMY1A/AMY2A copy number and
metabolic traits in D.E.S.I.R
The associations between metabolic quantitative traits
(except BMI) and enzymatic activity of AMY1/AMY2 or
AMY1A/AMY2A copy number were assessed through
linear regression models adjusted for age, sex, BMI, daily
alcohol consumption, smoking status, and the first two
principal components for ethnicity as previously described
[24]. We used the same models for the analysis of plasma
metabolites, with the same adjustments (including or not
BMI). The analysis of BMI was adjusted for age, sex, daily
alcohol consumption, smoking status, and the first two
principal components for ethnicity.
The effect of AMY1 or AMY2 activity at baseline on the
change in BMI during the 9-year follow-up was assessed
through a linear regression model adjusted for age at base-
line, sex, BMI at baseline, daily alcohol consumption,
smoking status, and the first two principal components
for ethnicity. The effect of BMI at baseline on the change
in AMY1 or AMY2 activity during the 9-year follow-up
was assessed through a linear regression model adjusted
for age at baseline, sex, AMY1 or AMY2 activity at base-
line, daily alcohol consumption, smoking status, and the
first two principal components for ethnicity.
Of note, BMI, aspartate aminotransferase, fasting insu-
lin, triglyceride levels, and the homeostasis model assess-
ment of beta-cell function (HOMA-2B) and of insulin
resistance (HOMA-2IR) were logarithmically transformed
before statistical analysis.
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Association analyses of glucose-related traits were per-
formed in non-diabetic individuals only. Association ana-
lyses of lipid traits were performed in participants who did
not use any lipid-lowering drugs at baseline. Association
analyses of blood pressure were performed in participants
who did not use any drugs against hypertension at baseline.
HOMA-2B and HOMA-2IR were calculated in
D.E.S.I.R. participants as previously described [24]. In each
regression model, traits were analyzed as dependent vari-
ables whilst copy number and enzymatic activities were
used as covariates.
Mendelian randomization analysis between BMI and AMY1/
AMY2 plasma enzymatic activity
The causal effect between BMI and AMY1 or AMY2
plasma enzymatic activity was estimated using a Mendelian
randomization approach [25, 26].
BMI→AMY1/AMY2 We used single nucleotide poly-
morphisms (SNPs) previously found to be genome-wide
significantly associated with BMI [27] as genetic instru-
ments for this analysis. We excluded 14 SNPs with known
pleiotropic effects on non-anthropometric traits (Additional
file 3). Among the remaining 83 SNPs, four were not
testable through the Illumina Metabochip DNA microarray
(rs12016871 within MTIF3 locus, rs16851483 within
RASA2 locus, rs17001654 within SCARB2 locus, and
rs9641123 within CALCR locus) and one SNP did not pass
the quality control (rs12566985 within the FPGT locus).
These five SNPs were replaced with proxies (R2 ≥ 0.64;
Additional file 3). For each of the 83 instrumental genetic
variables, we estimated causal effects of BMI on AMY1 or
AMY2 plasma enzymatic activity as ratios between the
SNP effect sizes on plasma AMY1 or AMY2 enzymatic
activity (measured in D.E.S.I.R.) over the SNP effect size on
BMI (obtained from Locke et al. [27]). Standard errors for
these causal estimates were derived by replacing in the
former calculations each SNP effect size on AMY1 or
AMY2 plasma enzymatic activity with its corresponding
standard error estimated within D.E.S.I.R. The 83 values of
causal effects of BMI on AMY1 or AMY2 plasma enzym-
atic activity were collapsed into single estimates (one for
each enzymatic activity) using inverse-variance weighting
[25]. Since no published genome-wide association studies
on amylase activities were available, we used as an alterna-
tive approach, the two-stage least-squares (TSLS) regres-
sion to estimate the causal effect of BMI on AMY1 or
AMY2 plasma enzymatic activity using D.E.S.I.R. data. This
analysis used as the instrumental variable the genetic risk
score, calculated as the sum of alleles increasing BMI over
the 83 selected SNPs. We did not observe any residual ef-
fect of BMI-associated SNPs on amylase activities (P > 0.2).
To ensure that cryptic pleiotropic effects among the 83
SNPs were not influencing our estimates of causal effect of
BMI on AMY1 and AMY2 plasma enzymatic activities,
we used Egger regression to test for the significance of
the intercept [28]. We found no significant effect of
pleiotropy (P = 0.41 for AMY1 activity, and P = 0.49 for
AMY2 activity).
AMY1/AMY2→ BMI We were unable to use AMY1A or
AMY2A copy number as instrumental variables to assess the
inverse causation between AMY1 or AMY2 plasma enzym-
atic activity and BMI as they both showed a residual associ-
ation with BMI after adjusting for the corresponding plasma
enzymatic activity (P < 0.001; Additional file 4). We therefore
looked for other instruments by testing the association be-
tween SNP genotyped on the Metabochip DNA microarray
(Illumina) and AMY1 or AMY2 plasma enzymatic activity in
the D.E.S.I.R. participants. This association was assessed
using linear regression of AMY1 or AMY2 plasma enzymatic
activity on genotyped SNP adjusted for age, sex, BMI, and
the first two principal components for ethnicity. Subse-
quently, the significant associations between SNPs and
AMY1 or AMY2 plasma enzymatic activity (after Bonferroni
correction: P < 4× 10−7 = 0.05÷124,571 tested SNPs) were
confirmed in ABOS. The combined analyses were performed
using a weighted inverse normal method via the function
“metagen”, with a fixed effect, in the “META” R package. No
heterogeneity was observed (P > 0.05). A good instrument
was consequently defined as a SNP significantly associ-
ated (P < 4 × 10−7) with AMY1 or AMY2 plasma enzym-
atic activity, without showing any residual association
with BMI (P > 0.05). Given these instruments, the causal
effect of AMY1 or AMY2 plasma enzymatic activity on
BMI was estimated using TSLS regression as imple-
mented in the R package ivpack (R function ivreg).
Association analyses between AMY1A copy number and
obesity risk
The association between obesity and AMY1A copy num-
ber was assessed by a logistic regression model adjusted
for age and sex in the two case-control studies. The
combined analysis was performed using a weighted in-
verse normal method via the function “metagen”, with a
fixed effect, in the “META” R package. No heterogeneity
was observed for this combined analysis (P = 0.14).
All genetic analyses were performed under an additive
model. All statistical analyses were performed using IBM
SPSS (version 14.0) or R (version 3.0).
Results
Association study between plasma enzymatic activity of
AMY1 or AMY2 and metabolic traits in D.E.S.I.R.
After adjustment for clinical and ethnic confounders, a
significant association was found between plasma enzym-
atic activity of AMY1 or AMY2 and lower BMI in the
French D.E.S.I.R. participants (β = –0.0013 ± 0.0002 kg/
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m2, P = 2.4 × 10−13; β = –0.0024 ± 0.0003 kg/m2, P = 2.4 ×
10−13, respectively; Table 1). Importantly, the effects of
AMY1 and AMY2 activities seemed partly independent
as they remained significant when both AMY1 and
AMY2 activities were added in the same regression
model (β = –0.0012 ± 0.0002 kg/m2, P = 2.8 × 10−12; β
= –0.0021 ± 0.0003 kg/m2, P = 4.2 × 10−12, respectively).
Furthermore, in non-diabetic participants, we identified a
significant association between AMY1 or AMY2 activity
and lower fasting plasma glucose levels (β =–0.0019 ±
0.0006 mmol/L, P = 1.4 × 10−3; β =–0.0026 ± 0.0010 mmol/
L, P = 9.2 × 10−3, respectively; Table 1), as well as higher
beta-cell function modeled by HOMA-2B (β = 0.0010 ±
0.0004, P = 9.0 × 10−3; β = 0.0017 ± 0.0006, P = 4.6 × 10−3,
respectively; Table 1). These associations remained signifi-
cant after the inclusion of AMY1 and AMY2 activities in
the same regression model (P < 0.05). We also found that
AMY2 activity was associated with higher fasting serum in-
sulin levels (β = 0.0025 ± 0.0009 pmol/L, P = 7.5 × 10−3;
Table 1). However, neither AMY2 activity nor AMY1 activ-
ity were found to be associated with insulin resistance
(modeled by HOMA-2IR; P > 0.05; Table 1).
Regarding lipid traits, we found that AMY1 activity
was associated with higher high-density lipoprotein chol-
esterol levels (β = 0.0015 ± 0.0005 mmol/L, P = 2.1 × 10
−3; Table 1), as well as higher apolipoprotein A1 levels
(β = 0.0008 ± 0.0003 g/L, P = 0.016; Table 1).
Furthermore, we identified a significant association be-
tween AMY1 activity and higher aspartate aminotransferase
levels (β = 0.0017 ± 0.0004 IU/I, P = 4.1 × 10−5; Table 1), and
AMY2 activity was found to be modestly associated with
lower systolic blood pressure (SBP; β = -0.067 ± 0.029 mm
Hg, P = 0.020; Table 1).
Association study between AMY1A/AMY2A copy number
and metabolic traits in D.E.S.I.R.
When analyzing copy number of AMY1A and AMY2A in
D.E.S.I.R. participants through ddPCR (Additional files 5
and 6), we confirmed that even AMY1A copy numbers
were more frequent than odd AMY1A copy numbers
(Additional files 5 and 6), as shown by Usher et al. [7].
Furthermore, we confirmed that the copy numbers of
AMY1A and AMY2A were nearly always both even or both
odd (Additional file 6) [7, 8, 10]. Although AMY1A or
AMY2A copy number was significantly correlated with
AMY1 or AMY2 plasma enzymatic activity, respectively
(Spearman test: R2 = 0.34, P < 2.2 × 10−16; R2 = 0.12, P <
2.2 × 10−16, respectively; Fig. 1a and b), we only found a
nominal association between AMY1A copy number and
lower BMI (β =–0.0018 ± 0.0009 kg/m2 per AMY1A copy,
P = 0.044; Additional file 7). Of note, we found that ddPCR-
estimated AMY1A copy number is highly correlated with
AMY1A copy number previously estimated by qPCR
(Spearman test: R2 = 0.86, P < 2.2 × 10−16; Additional file 8)
Table 1 Association between plasma enzymatic activity of AMY1 or AMY2 and metabolic traits in D.E.S.I.R.
Traits/disorders AMY1 AMY2
n Effect size ± SEa P value n Effect size ± SEa P value
BMI (kg/m2) 3673 −0.0013 ± 0.0002 2.4 × 10−13 3905 −0.0024 ± 0.0003 2.0 × 10−16
FG (mmol/L) 3629 −0.0019 ± 0.0006 1.4 × 10−3 3860 −0.0026 ± 0.0010 9.2 × 10−3
FI (pmol/L) 3625 0.0003 ± 0.0006 0.63 3856 0.0025 ± 0.0009 7.5 × 10−3
HOMA-2B 3343 0.0010 ± 0.0004 9.0 × 10−3 3548 0.0017 ± 0.0006 4.6 × 10−3
HOMA-2IR 3343 0.0004 ± 0.0005 0.40 3548 0.0007 ± 0.0008 0.36
HDL (mmol/L) 3432 0.0015 ± 0.0005 2.1 × 10−3 3637 −0.0005 ± 0.0008 0.58
LDL (mmol/L) 3427 0.0006 ± 0.0011 0.61 3632 −0.0006 ± 0.0019 0.74
TG (mmol/L) 3463 0.0003 ± 0.0006 0.68 3673 0.0003 ± 0.0010 0.81
ApoB (g/L) 3463 0.0001 ± 0.0003 0.83 3673 −0.0008 ± 0.0005 0.11
ApoA1 (g/L) 3463 0.0008 ± 0.0003 0.016 3673 −0.0009 ± 0.0005 0.10
SBP (mm Hg) 3245 −0.0063 ± 0.017 0.71 3452 −0.067 ± 0.029 0.020
DBP (mm Hg) 3245 0.0010 ± 0.011 0.93 3452 −0.013 ± 0.019 0.48
GGT (IU/L) 3744 −0.0025 ± 0.042 0.95 3980 0.021 ± 0.075 0.79
ALT (IU/L) 3741 0.032 ± 0.021 0.13 3977 −0.025 ± 0.035 0.47
AST (IU/L) 3741 0.0017 ± 0.0004 4.1 × 10−5 3977 0.0002 ± 0.0007 0.76
aEffect size according to adjusted linear regression model. BMI, AST, FI, HOMA-2B, HO MA-2IR, and TG were logarithmically transformed before statistical analysis
ALT alanine aminotransferase, AMY1 salivary amylase, AMY2 pancreatic amylase, ApoA1 apolipoprotein A1, ApoB apolipoprotein B, AST aspartate aminotransferase,
BMI body mass index, CI confidence interval, DBP diastolic blood pressure, FG fasting plasma glucose, FI fasting serum insulin, GGT gamma-glutamyl transferase,
HDL high-density lipoprotein, HOMA-2B homeostasis model assessment of beta-cell function, HOMA-2IR homeostasis model assessment of insulin resistance, LDL
low-density lipoprotein cholesterol, SBP systolic blood pressure, SE standard error, TG triglyceride
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in 2137 participants from D.E.S.I.R. [3]. Furthermore,
among these 2137 samples previously assessed, we con-
firmed a highly significant association between ddPCR-
estimated AMY1A copy number and lower BMI (β =–
0.0043 ± 0.0011 kg/m2 per AMY1A copy, P = 1.7 × 10−4;
Additional files 9 and 10). However, as tackled above, the
association between AMY1A copy number and lower BMI
was only nominal when we analyzed the whole sample set
from D.E.S.I.R. (Additional files 7, 9 and 10).
We did not find other significant associations between
AMY1A or AMY2A copy number and metabolic traits
(P > 0.05; Additional file 7).
Assessment of the causal effect between AMY1/AMY2
plasma enzymatic activity and BMI in D.E.S.I.R.
A Mendelian randomization analysis was subsequently per-
formed to assess causal effects explaining the complex rela-
tionship between BMI and AMY1 or AMY2 activity. We
found evidence of a causal negative effect of BMI on both
AMY1 (βcausal =–4.15 ± 1.66 IU/L per kg/m
2, P = 0.012;
Table 2) and AMY2 (βcausal =–2.53 ± 0.94 IU/L per kg/m
2,
P = 7.1 × 10−3; Table 2) plasma enzymatic activities. These
significant effects were confirmed using the TSLS regres-
sion (Table 2).
Assessing the inverse relationship (AMY1/AMY2→BMI)
turned out to be challenging as we could use neither
AMY1A nor AMY2A copy numbers as genetic instruments.
Indeed, we found a significant residual association between
AMY1A or AMY2A copy number and BMI when adjusting
for the corresponding plasma enzymatic activity (P < 0.001,
Additional file 4). As no genome-wide association study for
AMY1 or AMY2 plasma enzymatic activity has been
performed thus far, we assessed the association between
124,571 SNPs genotyped through the Metabochip DNA
microarray and AMY1 or AMY2 activity in D.E.S.I.R. partic-
ipants, and confirmed the identified associations in another
French cohort study (ABOS) in order to find valid genetic
instruments. We found one SNP strongly associated with
AMY1 activity (PRH1-PRR4 rs10492100: P= 3.3 × 10−11;
Table 3) and two SNPs strongly associated with AMY2 ac-
tivity (AMY2B rs12075225: P = 2.0 × 10−71; ABO rs507666:
P= 1.3 × 10−8; Table 3). SNP rs12075225 could not be con-
sidered as instruments into the Mendelian randomization
analysis as we found a residual association between
rs12075225 and BMI when adjusting for AMY2 activity
(P < 0.05). However, we were able to use rs10492100 and
rs507666 as instruments to assess the causal effect of
AMY1 and AMY2 activities, respectively, on BMI. When
using TSLS regression with these instruments, we did not
find a significant causal relationship of AMY1 or AMY2
activity on BMI (P > 0.05; Table 2).
Next, we took advantage of the prospective D.E.S.I.R.
study design with measured AMY1 (n = 679) or AMY2 (n =
705) plasma enzymatic activity after 9 years of follow-up
(Additional file 1). Indeed, although confounding can still be
present in prospective studies, having consistent results be-
tween baseline and follow-up data reinforces the significance
of the causal effect estimated besides using Mendelian
randomization tools. We found a significant negative effect
of BMI at baseline on the change in AMY1 activity (β=–
0.20 ± 0.08 IU/L, P= 0.014) or AMY2 activity (β=–0.18 ±
0.06 IU/L, P= 3.0 × 10−3) during the 9-year follow-up, which
is in line with the results of the Mendelian randomization
analyses showing that BMI negatively impacts amylase activ-
ity. Nonetheless, we also identified a significant negative
contribution of AMY1 activity at baseline to the change in
BMI during the 9-year follow-up (n = 2796; β=–0.0062 ±
0.0027 kg/m2, P = 0.022), which would imply a bidirectional
causal negative effect in the relationship between BMI and
AMY1 plasma enzymatic activity. The association between
AMY2 activity at baseline and the change in BMI during
the 9-year follow-up was not significant (P > 0.05).
Association study between AMY1A copy number and
obesity in adults and children/adolescents
The uncertainty about the causal effect of lower AMY1A
copy number (or AMY1 activity) to higher BMI prompted
us to assess the association between AMY1A copy number
and obesity risk in two French case-control studies, one
including 1179 obese adults and 2220 controls, and the
other one including 785 obese children/adolescents and
712 controls (Additional file 2; Additional files 11 and 12).
Fig. 1 Correlation analyses between (a) AMY1A copy number, AMY1 activity, and BMI or (b) AMY2A copy number, AMY2 activity, and BMI in
D.E.S.I.R. Data are (unadjusted) Spearman correlations with P values
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In the French adults, we found that the mean number of
AMY1A copies was lower in obese subjects (6.8 ± 2.5;
Table 4) than in controls (7.0 ± 2.6; Table 4), although this
difference was not significant when we adjusted the logis-
tic regression model for both age and sex (P = 0.13;
Table 4). In contrast, in the French children/adolescents,
we found a significant association between AMY1A copy
number and lower obesity risk (odds ratio (OR) per
estimated copy 0.94; 95% confidence interval (CI), 0.90–
0.98; P = 7.1 × 10−3; Table 4). When we combined the two
case-control studies in adults and youths, we identified a
significant contribution of AMY1A copy number to lower
obesity risk (OR per estimated copy 0.97; 95% CI, 0.94–
0.99; P = 6.8 × 10−3; heterogeneity: P = 0.14; Table 4).
Association analysis between known BMI-associated
plasma metabolites and AMY1/AMY2 plasma enzymatic
activity in D.E.S.I.R.
Finally, we aimed to assess the association between 36 plasma
metabolites known to be associated with BMI [23] and
AMY1 or AMY2 plasma enzymatic activity in 718 D.E.S.I.R.
participants. First, we confirmed a significant association be-
tween these metabolites and BMI in these participants,
except for palmitoyl sphingomyelin, which was found to be
only metabolite nominally associated with BMI (P= 0.07), al-
though with the same published effect size direction (β < 0)
[23]. Then, we identified significant associations between sev-
eral metabolites, including branched-chain amino acids (iso-
leucine, isovalerylcarnitine, and leucine), and AMY1 and/or
AMY2 plasma enzymatic activity (Additional file 13), with an
effect size direction opposite to the one of BMI effect on the
same metabolites (Additional file 13). Interestingly, lactate
was significantly associated with higher AMY1 activ-
ity, when the regression model was adjusted or not for
BMI (β = 0.050 ± 0.020, P = 5.8 × 10−3; BMI-adjusted: β =
0.058 ± 0.020, P = 1.6 × 10−3; Additional file 13).
Discussion
In the present study, we found that plasma enzymatic
activities of both AMY1 and AMY2 were markedly associ-
ated with lower BMI and some other related metabolic
traits, including lower fasting plasma glucose levels, higher
pancreatic beta-cell function, and better lipid profiles, link-
ing starch hydrolysis and metabolism in humans. Although
AMY1 or AMY2 plasma enzymatic activity was significantly
correlated with the number of copies of AMY1A or AMY2A,
Table 2 Estimates of causal relationship between BMI and AMY1 or AMY2 plasma enzymatic activity, using two different methods
Relationships
to assess
Inverse variance weighting method Two-stage least squares method
Effect size ± SE P value Instrument Effect size ± SE P value Instrument
BMI→ AMY1
(n = 3673)
−4.15 ± 1.66 0.012 GRS based on
83 SNPs




−2.53 ± 0.94 7.1 × 10−3 GRS based on
83 SNPs








NAa NAa NAa 0.041 ± 0.097 0.67 rs507666
(ABO)
aThe inverse variance weighting scheme could not be properly applied to estimate the causal effect of AMY1 or AMY2 plasma enzymatic activity on BMI as to our
knowledge, no data on association between SNPs and those activities have been published before
AMY1 salivary amylase, AMY2 pancreatic amylase, BMI body mass index, GRS genetic risk score, NA not applicable, SE standard error, SNP single
nucleotide polymorphism
Table 3 SNPs found to be significantly associated with AMY1 or AMY2 plasma enzymatic activity in D.E.S.I.R. participants, with a
replication study in ABOS participants
SNP ID Chr: position
(Build 37)
Closest gene Tested allele/
Other allele
Cohort study n MAF Effect size ±
SE per allele
P value
AMY1 rs10492100 12:11085820 PRH1-PRR4 C / T Discovery 3673 0.21 −2.36 ± 0.39 6.6 × 10−10
Replication 488 0.25 −2.31 ± 0.85 6.9 × 10−3
Meta-analysis 4227 – −2.35 ± 0.35 3.3 × 10−11
AMY2 rs12075225 1:104115017 AMY2B A / C Discovery 3905 0.10 5.11 ± 0.29 3.3 × 10−70
Replication 488 0.07 3.48 ± 1.04 9.1 × 10−4
Meta-analysis 4227 – 4.99 ± 0.28 2.0 × 10−71
AMY2 rs507666 9:136149399 ABO A / G Discovery 3905 0.22 −1.17 ± 0.22 5.7 × 10−8
Replication 488 0.21 −1.21 ± 0.60 4.4 × 10−2
Meta-analysis 4227 – −1.17 ± 0.21 1.3 × 10−8
AMY1 salivary amylase, AMY2 pancreatic amylase, Chr chromosome, MAF minor allele frequency, SE standard error
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respectively (Fig. 1a and b), we found a nominal association
between AMY1A copy number and lower BMI in middle-
aged French adults. However, we identified a significant as-
sociation between AMY1A copy number and lower risk of
obesity in French children, which is in line with our previous
study performed in Mexican children [9].
The present study also assessed the hypothesis that pan-
creatic amylase genes (instead of salivary amylase gene)
could actually drive the association with BMI [10]. However,
we did not find any significant marginal association between
AMY2A copy number and BMI, which makes unlikely a
major role for pancreatic amylase gene. Yet, we only geno-
typed AMY2A copy number and not AMY2B copy number,
which is a limitation of our study, even if Usher et al. [7]
showed that AMY2A copy number was similar to AMY2B
copy number in approximately 95% of haploid genotypes.
Through a Mendelian randomization analysis, we identified
a causal negative effect of BMI on plasma enzymatic activities
of both AMY1 and AMY2. In contrast, we failed to find any
causal effect of AMY1 or AMY2 plasma enzymatic activity
on BMI, although this specific analysis likely lacked sufficient
statistical power. Indeed, since we could use neither AMY1A
nor AMY2A copy number as a genetic instrument for the
analysis, we were deprived of the possibility to utilize some of
the strongest potential instruments available. Despite this
limitation, we were able to find surrogate instruments that
were, however, poorly associated with plasma enzymatic ac-
tivities of AMY1 and AMY2 compared to their correspond-
ing gene copy number. In addition, since no large genome-
wide association study for AMY1 or AMY2 plasma enzym-
atic activity has been performed so far, we were left with a
very limited number of useable instruments. The prospective
data available in D.E.S.I.R. further supported the negative ef-
fect of BMI on AMY1 and AMY2 activities. However, we
also found a significant negative contribution of AMY1 activ-
ity at baseline to the change in BMI during the 9 years of
follow-up, which implies a possibly causative impact of
AMY1 activity on decreased adiposity. This was supported
by the present results obtained from our obesity case-control
study, showing a significant contribution of AMY1A copy
number to decreased obesity risk in French children.
The impact of AMY1 activity and AMY1A copy number
on adiposity is therefore complex and it seems to interact
with the metabolic effect of complex carbohydrate digestion
by the gut microflora. Our recent independent digital PCR
analyses of AMY1A copy number in Mexican children [9]
and our present results in French youths found strong evi-
dence that high AMY1A copy numbers protect against child-
hood obesity in this high-starch diet populations. In contrast,
in French middle-aged adults from the general population,
we failed to reproduce these findings. The difference between
adults and children may be due to the fact that the heritabil-
ity of BMI is higher in childhood than in adulthood [29, 30],
optimizing the identification of significant associations
between genetic events and obesity risk. Furthermore, this
difference may be due to different gene–environment inter-
actions depending on age [29, 30]. For instance, youths may
eat more carbohydrates than adults (as the energy require-
ments of youths have been shown to parallel their growth
rate) [31]. In rodents, it was shown that the SNP at Amy1
locus strongly predicts weight gain after 8 weeks on a high-
fat, high-sucrose diet, with an associated enrichment in gut
bacteria observed in obesity states, which may mediate the
metabolic effect of Amy1 expression variation [15].
In D.E.S.I.R., we found that AMY1 plasma enzymatic ac-
tivity was significantly associated with higher plasma lactate
levels independently of BMI. Lactate is a well-known prod-
uct of complex carbohydrate fermentation by the gut micro-
biota [32]. It has been proposed that decrease in the lactate/
butyrate ratio can generate an extra 20 calories/day, which
may lead to an extra kilogram for weight over a year [32].
Therefore, we suggest that amylase activity, which is associ-
ated with higher lactate production, may protect against
obesity, especially in individuals with a high-starch diet.
Conclusions
In conclusion, our systems biology study performed in a
prospectively followed population-based European cohort
suggests a bidirectional relationship between AMY1 plasma
enzymatic activity and adiposity. Altogether, low AMY1 ac-
tivity due to both genetic and environmental events may
modulate human colonic microbiota fermentation of oligo-
saccharides into short-chain fatty acids via lactate regula-
tion [32], which may have a negative impact on energy
harvest, and therefore may aggravate obesity. Further stud-
ies are warranted to assess the validity of this hypothesis
that, if confirmed, may have clinical implications in obesity
treatment [33].
Table 4 Association between AMY1A copy number and obesity risk
Study Obese cases Controls OR (95% CI)b P value
n AMY1A copiesa n AMY1A copiesa
Adults 1179 6.8 ± 2.5 2220 7.0 ± 2.6 0.98 (0.95–1.01) 0.13
Children/Adolescents 785 7.0 ± 2.6 712 7.3 ± 2.7 0.94 (0.90–0.98) 7.1 × 10−3
Combined analysis – – – – 0.97 (0.94–0.99) 6.8 × 10−3
aData are means ± standard deviation
bOdds ratio per AMY1A copy from a logistic regression adjusted for age and sex
AMY1A salivary amylase gene, CI confidence interval, OR odds ratio
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